NeuroPace Files 8-K on Operations & Financial Condition

Ticker: NPCE · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1528287

Neuropace Inc 8-K Filing Summary
FieldDetail
CompanyNeuropace Inc (NPCE)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: financial-condition, regulation-fd, corporate-update

TL;DR

**NeuroPace just dropped an 8-K on its financials, signaling an update on company performance.**

AI Summary

NeuroPace Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition, as well as to make a Regulation FD disclosure. This filing indicates that the company is providing an update on its financial performance, which is crucial for investors to understand the company's current health and future prospects. For shareholders, this matters because it offers transparency into the company's financial standing, potentially influencing stock valuation and investment decisions.

Why It Matters

This filing provides an update on NeuroPace's financial health, which is essential for investors to assess the company's performance and make informed decisions.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial information and does not inherently present a high risk, though the content of the disclosed financials could be positive or negative.

Analyst Insight

A smart investor would await the full details of the 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure' mentioned in this 8-K to understand the specific financial performance and any new material information before making investment decisions.

Key Players & Entities

  • NeuroPace Inc. (company) — the registrant filing the 8-K
  • January 8, 2024 (date) — date of earliest event reported
  • 001-40337 (other) — Commission File Number
  • NPCE (other) — Trading Symbol on Nasdaq Global Market

FAQ

What is the purpose of NeuroPace Inc.'s 8-K filing dated January 8, 2024?

The purpose of NeuroPace Inc.'s 8-K filing dated January 8, 2024, is to report on its results of operations and financial condition, and to make a Regulation FD Disclosure, as indicated under 'ITEM INFORMATION: Results of Operations and Financial Condition' and 'ITEM INFORMATION: Regulation FD Disclosure'.

What is NeuroPace Inc.'s trading symbol and on which exchange is it registered?

NeuroPace Inc.'s trading symbol is NPCE, and its common stock is registered on the Nasdaq Global Market, as stated under 'Title of each class' and 'Name of each exchange on which registered'.

What is the business address and phone number for NeuroPace Inc.?

NeuroPace Inc.'s business address is 455 N. Bernardo Avenue, Mountain View, CA 94043, and its business phone number is (650) 237-2700, according to the 'BUSINESS ADDRESS' section of the filing.

What is the state of incorporation for NeuroPace Inc.?

NeuroPace Inc. is incorporated in Delaware, as specified under 'State or Other Jurisdiction of Incorporation'.

What is the Central Index Key (CIK) for NeuroPace Inc.?

The Central Index Key (CIK) for NeuroPace Inc. is 0001528287, as listed under 'COMPANY DATA: CENTRAL INDEX KEY'.

Filing Stats: 638 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2024-01-08 07:05:58

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value per share NPCE Nasdaq Glo

Filing Documents

02

Item 2.02 Results of Operations and Financial Condition. On January 8, 2024, NeuroPace issued a press release announcing its preliminary unaudited revenue and cash balance for the fiscal quarter and year ended December 31, 2023, as well as providing a summary of business updates. A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information in this Item 2.02 (including the exhibit hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

01

Item 7.01 Regulation FD Disclosure NeuroPace has prepared an investor presentation for use at the J.P. Morgan Healthcare Conference on January 11, 2024, at 7:30 a.m. Pacific Time. A copy of the investor presentation is attached hereto as Exhibit 99.2. A copy of the investor presentation will also be accessible on NeuroPace's website at https://investors.neuropace.com/news-and-events/presentations. The foregoing information in this Item 7.01 (including the exhibit hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release dated January 8, 2024 99.2 Investor Presentation dated January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NeuroPace, Inc. Dated: January 8, 2024 By: /s/ Irina Ridley Irina Ridley Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.